Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy Study

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

• S. Jalal, S. Bhatia, L. Einhorn, R. Ansari, N. Bechar, R. Govindan, K. Koneru, P. Bedano, J. Wu, N. Hanna. Paclitaxel (P) plus bevacizumab (B) in patients (pts) with Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy trial from the Hoosier Oncology Group LUN05-99. Accepted to the ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL

Manuscripts/Articles:

• Jalal S, Bedano P, Einhorn L, Bhatia S, Ansari R, Bechar N, Koneru K, Govindan R, Wu J, Yu M, Schneider B, Hanna N. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group. J Thorac Oncol. 2010 Dec;5(12):2008-11. doi: 10.1097/JTO.0b013e3181f77b6e. See abstract.